Clinical-stage radiopharmaceutical company Oncoinvent ASA (Euronext Growth Oslo:ONCIN) on Monday announced updated 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis.
The trial, which closed for recruitment at the end of 2023, is now in long-term follow-up.
In the study, 10 patients received a single intraperitoneal dose of 7 MBq Radspherin. At the 12-month follow-up reported in November 2024, only one patient had experienced peritoneal recurrence.
The 18-month data showed no new recurrences, maintaining the recurrence rate at 10%. In comparable populations treated with best standard of care, approximately 40% of patients would typically have had a recurrence by this stage.
LEO Pharma reports positive phase 2b results for temtokibart in atopic dermatitis
New England Biolabs achieves B Corporation recertification
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial